BioMarin Pharmaceutical Q4 Earnings: A Mixed Bag for Therapeutic Stocks.

BioMarin Pharmaceutical's Q4 revenues rose 17% YoY to $874.6 million, beating analysts' expectations by 4.8%. The company's stock is down 12% since reporting, while Novavax reported revenues of $147.1 million, up 66.6% YoY, with a 57.4% beat on analysts' estimates. Both companies are part of the therapeutics sector, which faces headwinds from rising drug pricing scrutiny, regulatory unknowns, and competition from larger pharmaceutical companies.